Cargando…

Durvalumab in NSCLC: latest evidence and clinical potential

Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Unceta, Nerea, Burgueño, Isabel, Jiménez, Elizabeth, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187424/
https://www.ncbi.nlm.nih.gov/pubmed/30344651
http://dx.doi.org/10.1177/1758835918804151
_version_ 1783363018861576192
author Muñoz-Unceta, Nerea
Burgueño, Isabel
Jiménez, Elizabeth
Paz-Ares, Luis
author_facet Muñoz-Unceta, Nerea
Burgueño, Isabel
Jiménez, Elizabeth
Paz-Ares, Luis
author_sort Muñoz-Unceta, Nerea
collection PubMed
description Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease settings, and combinations with other therapies are being actively investigated. Durvalumab, a monoclonal antibody directed against the programmed death ligand 1, has demonstrated significant activity in NSCLC, including increased progression-free survival rates after chemoradiation for unresectable stage III disease, with a favourable safety profile. Clinical trials, including phase III studies, are ongoing as monotherapy and in combination with chemotherapy, radiotherapy and other immunotherapies, such as the anti-cytotoxic T-lymphocyte antigen 4 drug tremelimumab, in diverse stages of the disease.
format Online
Article
Text
id pubmed-6187424
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61874242018-10-19 Durvalumab in NSCLC: latest evidence and clinical potential Muñoz-Unceta, Nerea Burgueño, Isabel Jiménez, Elizabeth Paz-Ares, Luis Ther Adv Med Oncol Review Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease settings, and combinations with other therapies are being actively investigated. Durvalumab, a monoclonal antibody directed against the programmed death ligand 1, has demonstrated significant activity in NSCLC, including increased progression-free survival rates after chemoradiation for unresectable stage III disease, with a favourable safety profile. Clinical trials, including phase III studies, are ongoing as monotherapy and in combination with chemotherapy, radiotherapy and other immunotherapies, such as the anti-cytotoxic T-lymphocyte antigen 4 drug tremelimumab, in diverse stages of the disease. SAGE Publications 2018-10-11 /pmc/articles/PMC6187424/ /pubmed/30344651 http://dx.doi.org/10.1177/1758835918804151 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Muñoz-Unceta, Nerea
Burgueño, Isabel
Jiménez, Elizabeth
Paz-Ares, Luis
Durvalumab in NSCLC: latest evidence and clinical potential
title Durvalumab in NSCLC: latest evidence and clinical potential
title_full Durvalumab in NSCLC: latest evidence and clinical potential
title_fullStr Durvalumab in NSCLC: latest evidence and clinical potential
title_full_unstemmed Durvalumab in NSCLC: latest evidence and clinical potential
title_short Durvalumab in NSCLC: latest evidence and clinical potential
title_sort durvalumab in nsclc: latest evidence and clinical potential
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187424/
https://www.ncbi.nlm.nih.gov/pubmed/30344651
http://dx.doi.org/10.1177/1758835918804151
work_keys_str_mv AT munozuncetanerea durvalumabinnsclclatestevidenceandclinicalpotential
AT burguenoisabel durvalumabinnsclclatestevidenceandclinicalpotential
AT jimenezelizabeth durvalumabinnsclclatestevidenceandclinicalpotential
AT pazaresluis durvalumabinnsclclatestevidenceandclinicalpotential